VivoSim Labs' NAMkind™ platform shows 87.5% predictive accuracy for liver toxicity, enhancing drug safety and reducing development costs. VivoSim Labs, Inc. announced the successful performance of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results